Vir Biotechnology (NYSE:VIR) shares reached a new 52-week high on Thursday . The stock traded as high as $16.60 and last traded at $16.52, with a volume of 2924 shares changing hands. The stock had previously closed at $15.26.
A number of research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Vir Biotechnology from a hold rating to a sell rating in a research report on Saturday, January 11th. Goldman Sachs Group began coverage on shares of Vir Biotechnology in a research report on Tuesday, November 5th. They issued a buy rating and a $37.00 target price for the company. Robert W. Baird began coverage on shares of Vir Biotechnology in a research note on Wednesday, November 13th. They set a neutral rating for the company. Cowen began coverage on Vir Biotechnology in a report on Tuesday, November 19th. They set a buy rating on the stock. Finally, JPMorgan Chase & Co. assumed coverage on Vir Biotechnology in a report on Tuesday, November 5th. They set an overweight rating and a $25.00 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Vir Biotechnology currently has a consensus rating of Buy and an average target price of $29.00.
The stock has a 50-day moving average price of $12.86.
Vir Biotechnology (NYSE:VIR) last released its quarterly earnings results on Tuesday, November 19th. The company reported ($4.60) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($3.71) by ($0.89). The firm had revenue of $1.40 million for the quarter.
About Vir Biotechnology (NYSE:VIR)
Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.
Read More: What is a Call Option?
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
See the original post here:
Vir Biotechnology (NYSE:VIR) Reaches New 52-Week High at $16.60 - Riverton Roll
Recommendation and review posted by G. Smith
